Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

BMY 58.75 -0.86 (-1.44%)
price chart
AbbVie Inc, Bristol-Myers Squibb Co Look Set To Drive Cancer Market
AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Co (NYSE:BMY) are looking to gain marketing approval for their jointly developed blood cancer drug, elotuzumab in the near future.
FDA Accepts Biologics License Application For Empliciti As Adjunct Treatment ...  Immuno-Oncology News
BMS' myeloma treatment accepted for priority review  PMLiVE
Bristol Myers Squibb Co (BMY) Files Form 4 Insider Selling : Lamberto ...
Bristol Myers Squibb Co (BMY): Lamberto Andreotti , director of Bristol Myers Squibb Co sold 23,200 shares on Sep 2, 2015.
Jefferies Rating Update on Bristol-Myers Squibb Company (NYSE:BMY)  American Trade Journal
Investors Buy Bristol-Myers Squibb on Weakness Following Insider Selling (BMY)  Dakota Financial News
Notable Runners -Exxon Mobil Corporation (NYSE:XOM), Bristol-Myers Squibb ...
Bristol-Myers Squibb Company will host a teleconference on Tuesday, September 8 at 8 a.m. EDT (6 a.m. MDT) to review data presented at the 16th Annual World Conference on Lung Cancer (WCLC) in Denver, CO.
Large Inflow of Money Witnessed in Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE:BMY) had a weak trading session and its shares were last down at $59.49, down -1.12% or -1.85 points.
Bristol-Myers Squibb (BMY) Obtians Exclusive Right to Acquire Promedior and ...  StreetInsider.com
Bristol-Myers Squibb Company (NYSE:BMY) Given PT Range of $36-$80  Markets Daily
Piper Jaffray Upgrades Bristol-Myers Squibb, Sees Valuation As Fair
With the meaningful decline in the share price since Bristol-Myers Squibb Co (NYSE: BMY) announced its Q2 earnings, the stock is now trading close to its fair value.
Bristol-Myers Squibb Co (BMY) Stock Update  Bidness ETC
Bristol-Myers Squibb (BMY) Stock Gets Rating Upgrade at Piper Jaffray  TheStreet.com
FDA Pushes Back Decision on Expanded Use of Bristol-Myers Squibb Drug Opdivo
The Food and Drug Administration pushed back the decision date on an expanded use of Bristol-Myers Squibb Co. BMY 2.42 % 's cancer drug Opdivo to Nov. 27, Bristol-Myers said Wednesday.
Bristol-Myers Squibb Co (NYSE:BMY) The Leukemia & Lymphoma Society ...  Markets Wired
Bristol-Myers Squibb Company (NYSE:BMY) Price Target Update  News Watch International
Buy The Dip On Bristol-Myers Squibb: J.P. Morgan
In a report published Tuesday, JP Morgan analyst Chris Schott maintained an Overweight rating on Bristol-Myers Squibb Co (NYSE: BMY), with a price target of $75.
Why Gilead Sciences, Inc. Can Easily Take Over Bristol-Myers Squibb Co
The only recent deal struck by Gilead has been the purchase of a small cancer firm, EpiTherapeutics Aps, earlier this year for $65 million.
Bristol-Myers Squibb Company (NYSE:BMY) Hold Rating Reiterated at Jefferies ...  OctaFinance.com
Large Outflow of Money Witnessed in Bristol-Myers Squibb Company  Money Flow Index
Bristol-Myers Squibb Becomes Oversold
But making Bristol-Myers Squibb Co. an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of BMY entered into oversold territory, changing hands as low as $51.82 per share.
Stock Highlights: Rex Energy Corporation (NASDAQ:REXX), Bristol-Myers Squibb ...
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world.